!"#$%"&#'$()*$#)"+,-*$%.,/"0.,")1$"2$(3.#($")."!&45"

"

6.,$"7-89$"0.,")1$"6.#$:"%;)1;#"-"+,-*$%.,/".0"

51-,$<"2$(3.#(;=;8;):"

Resources available for HIV in low and middle income countries, 1986-2010

We have done a lot…

!  >#3,$?$<$#)$<"(?-8$"93".0"@&7"3,$'$#A.#B"),$-)*$#)B"?-,$"-#<"

(933.,)"

!  4$?8;#$";#",-)$".0"#$%"@&7";#0$?A.#(";#"*-#:"?.9#),;$("

! 6.,$")1-#"CDC"*;88;.#"3$.38$".#"

!2E"

! 6;88;.#(".0".,31-#(",$?$;';#F"=-(;?"

$<9?-A.#B"1$-8)1B"(.?;-8"3,.)$?A.#"

But we can do better

5?-8$"93")."<-)$"F9;<$<"=:"-"G?.**.<;):"-33,.-?1H"

"!  >#(:()$*-A?"3,;.,;A(-A.#"-#<";#'$()*$#)"%;)1"8;*;)$<"=-(;(";#"?.9#),:"$3;<$*;.8.F:"-#<"?.#)$I)"

!  2$(.9,?$("(3,$-<")1;#8:"-?,.(("*-#:"3-,-88$8";#)$,'$#A.#("

!  +.?9(".#"<;(?,$)$";#)$,'$#A.#(",-)1$,")1-#".'$,-88",$(98)("8$-<;#F")."-"0,-F*$#)$<",$(3.#($"

New Investment Framework

SYNERGIES WITH DEVELOPMENT SECTORS Social protection; Education; Legal Reform; Gender equality; Poverty reduction; Gender-based violence; Health systems (incl. treatment of STIs, blood safety); Community systems; Employer practices.

CRITICAL ENABLERS

Social enablers • Political commitment &

advocacy • Laws, policies &

practices • Community mobilization • Stigma reduction • Mass media • Local responses, to

change risk environment

Programme enablers • Community-centered

design & delivery • Programme

communication • Management & incentives • Production & distribution • Research & innovation

Care & treatment

Male circumcision

Keeping people alive

BASIC PROGRAMME ACTIVITIES

Key populations

Children & mothers

Condoms

OBJECTIVES

Stopping new infections

Behaviour change

!

"

#!

#"

$!

$"

%!

%"

$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

Three investment scenarios Impact on the epidemic

>54"JK;88;.#(L"

M"NDO"

M"NDP"

M"QDO"

M"QDP"

M"PDO"

M"P" R$%"@&7"&#0$?A.#("

J*;88;.#(L"

K9(;#$(("-("9(9-8"M"NDO"

M"NDP"

M"QDO"

M"QDP"

M"PDO"

M"P" R$%"@&7"&#0$?A.#("

J*;88;.#(L"

!

"

#!

#"

$!

$"

%!

%"

$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

>54"JK;88;.#(L"

K9(;#$(("-("9(9-8"

&#'$()*$#)"0,-*$%.,/"

M"NDO"

M"NDP"

M"QDO"

M"QDP"

M"PDO"

M"P" R$%"@&7"&#0$?A.#("

J*;88;.#(L"

Three investment scenarios Impact on the epidemic

!

"

#!

#"

$!

$"

%!

%"

$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

>54"JK;88;.#(L"

2-3;<"(?-8$"93"

3,$';.9("3,.S$?A.#("

K9(;#$(("-("9(9-8"

&#'$()*$#)"0,-*$%.,/"

M"NDO"

M"NDP"

M"QDO"

M"QDP"

M"PDO"

M"P" R$%"@&7"&#0$?A.#("

J*;88;.#(L"

Three investment scenarios Impact on the epidemic

!

"

#!

#"

$!

$"

$!## $!#$ $!#% $!#& $!#" $!#' $!#( $!#) $!#* $!$!

>54"JK;88;.#(L"

E1$"#$%";#'$()*$#)"0,-*$%.,/"

+.?9(".#"%1-)"*-/$("-"<;T$,$#?$"

K-(;?"U,.F,-**$"

!?A';A$("

V,;A?-8"W#-=8$,("

5:#$,F;$("

!" #!" $!" %!" &!" '!" (!" )!" *!" +!"

#!!"

,'!! %'!-&++ $'!-%&+ $!!-$&+ #!!-#++ '!-++ .'! V4X"V.9#)"J?$88(Y*8L

V.'$,-F$

ART coverage in 2015 by CD4 count

!" #!" $!" %!" &!" '!" (!" )!" *!" +!"

#!!"

,'!! %'!-&++ $'!-%&+ $!!-$&+ #!!-#++ '!-++ .'! V4X"V.9#)"J?$88(Y*8L

V.'$,-F$

13.1 million (health)

CD4 350

15 million

T4P

Returns on investment of new investment framework (2011-2020)

Outcomes

Total infections averted More than 12 million

Infant infections averted 1.9 million

Deaths averted 7.4 million

Life years gained 29.4 million

New investment framework: the tipping point

R$%8:"$8;F;=8$"0.,"),$-)*$#)"

R$%8:";#0$?)$<"

New infections, behaviour change and treatment coverage in Botswana

Behaviour change

New infections and treatment coverage

Cost and economic returns 2011 to 2020

Cost/Returns Total additional investment (over 10 years) US$46.5 Billion

Future treatment need averted US$40 Billion

Life years gained US$1,060 per life year gained

Investment framework projections for new HIV infections

Optimized investment will lead to rapid declines in new HIV infections in many countries

V.**9#;):"*.=;8;Z-A.#"-((9*3A.#(";#")1$"

;#'$()*$#)"0,-*$%.,/""V.()"$#'$8.3$["?.**9#;):"*.=;8;(-A.#"?.*3.#$#)".0")1$"

?,;A?-8"$#-=8$,("""

"

////$!##//0!1%23/ //$!#'/0!1(/23// /$!$!/0#1!/23///!((9*3A.#(["

•  43567897:/5;<<=3>?@/58A85>?@//•  >3567897:/5;<<=3>?@/976B>57/:7C>B76@///•  377:/D;6/67<=3768E;3/;D/5;<<=3>?@/83:/C8@/F;6G769//•  377:/D;6/?68>3>3HI/H=>:8357I/9=A76B>9>;3/•  A86E5>A8E;3/;D/A7;AC7/C>B>3H/F>?J/K4L/

V.**9#;):"*.=;8;Z-A.#["*-/$("(?-8$"93"3.((;=8$""

•  R9*=$,".0"3$.38$")$()$<")1,.9F1"?.**9#;):"*.=;8;Z-A.#""

/$!#!M/&(/<>CC>;3/NLOPQ/// /$!#'M/#!+/<>CC>;3///

•  5$,';?$"<$8;'$,:"?.()("J),$-)*$#)L""

/$!#!M/0#)+/A76/@786////$!$!M/0#$'/A76/@786/N0#)/>3/C;F/>35;<7/5;=3?6>79Q//

/

•  4,;';#F"?.()("<.%#["0$%$,".9)3-A$#)"';(;)(B"?.**9#;):"(933.,)"($,';?$"*.<-8;A$("

•  K$\$,"@$-8)1"]9)?.*$("

V.**9#;):"*.=;8;Z-A.#[""

;#?,$-($("$T$?A'$#$(("•  O;<<=3>?@/<;2>C>98E;3/>3567897:/K4L/?79E3H/68?79/D;=6-

D;C:/>3/P83R83>8I/S><282F7I/T;=?J/UD6>58/83:/PJ8>C83:1///•  O;39>9?73?/5;3:;</=97/>3/A89?/#$/<;3?J9/&/E<79/J>HJ76/>3/

5;<<=3>E79/F>?J/H;;:/5;<<=3>?@/73H8H7<73?/NV73@8Q////•  K@A;?J7E58C/5>65=<5>9>;3/<;:7C/VF8S=C=-W8?8C/M//

–  5;67/>3?76B73E;3M//$&!I!!!/>3D75E;39/8B76?7:/;B76/?73/@7869/–  F>?J/7382C769M/&$!I!!!/>3D75E;39/8B76?7:I/F>?J/<;:79?/<86H>38C/>3567897/>3/5;9?9/

/

Investement framework allocation in 2015

E-#Z-#;-["-##9-8"#$%"@&7";#0$?A.#(B"NPQQMNPNP"

!/

$!!!!/

&!!!!/

(!!!!/

*!!!!/

#!!!!!/

#$!!!!/

#&!!!!/

#(!!!!/

$!##/ $!#$/ $!#%/ $!#&/ $!#'/ $!#(/ $!#)/ $!#*/ $!#+/ $!$!/

K-($8;#$"J=9(;#$(("-("9(9-8L"

&#'$()*$#)"+,-*$%.,/"

K-($8;#$"J=9(;#$(("-("9(9-8L"

&#'$()*$#)"+,-*$%.,/"

E-#Z-#;-["-##9-8"!&45"<$-)1(B"NPQQMNPNP"

!/

$!!!!/

&!!!!/

(!!!!/

*!!!!/

#!!!!!/

#$!!!!/

#&!!!!/

$!##/$!#$/$!#%/$!#&/$!#'/$!#(/$!#)/$!#*/$!#+/$!$!/

K-($8;#$"J=9(;#$(("-("9(9-8L"

&#'$()*$#)"+,-*$%.,/"

Resources available for HIV in low and middle income countries, globally, 2002-2010

Percentage of care and treatment expenditure from international sources

Few donors meet the development assistance targets

Net development assistance in 2001 as % of gross national income

Norway Luxembourg

Sweden Denmark

Netherlands Belgium

United Kingdom Finland Ireland France Spain

Switzerland Germany

Canada Austria

Australia Portugal

New Zealand United States

Japan Greece

Italy Korea

1.10% 1.09%

0.97% 0.90%

0.81%

0.50% 0.43% 0.41%

0.38% 0.33% 0.32% 0.32%

0.29% 0.26%

0.21% 0.20%

0.17% 0.15%

0.12%

0.64% 0.56%

0.55% 0.53%

0% 0.3% 0.5% 1% 1.2% 0.7%

Measuring national commitment to AIDS: the Domestic Investment Priority Index

SOURCE: UNAIDS expenditure data; WHO data on the burden disease; and economic data from the International Monetary Fund World Economic Outlook database

Economic growth in Africa, 1970–2010 Third-fastest growing region in the World

Three options for increasing domestic public HIV investment in Africa

Projected resource needs (in USD billion) Assumed increases of domestic contributions by BRICS and others within ability to pay (economic growth and towards Abudja targets)

LI 9.7

11.3 11.9

13.0 13.6 13.5 12.7 11.8 10.7 9.4 8.0

LMI

UMI

Developm

ent Assistance

Dom

estic financing XY4OT/

T;<7/Z=79E;39/

•  [J8?/867/?J7/9?68?7H>5/;A73>3H9/D;6/8/37F/:>8C;H=7/86;=3:/7\5>735@]/

•  U67/?J767/;2B>;=9/<>9-<8?5J79/27?F773/?J7/7A>:7<>5/83:/?J7/679A;397]/

•  [J>5J/867/?J7/D85?;69/?J8?/<8G7/>?/:>\5=C?/?;/958C7/=A/289>5/A6;H68<<7/5;<A;373?9]//

•  K;F/5;=C:/A86?3769/J7CA/>3/8AAC>58E;3/;D/?J7/4^/8AA6;85J/

The beginning of the end of AIDS is in our hands

Y785J>3H/A7;AC7/F>?J/976B>579M/_`8<AC79/D;6/$!#'/

V.'$,-F$"J3.398-A.#",$-?1$<L"

O;3:;<9/N:>95;6:83?/5;=AC79Q/ (!"/O;3:;<9/NJ>HJ/6>9G/A;AQ/ '!"/T7`/F;6G/ (!"/aTa/A6;H68<<79/ (!"/4bc/A6;H68<<79/ (!"/

6;88;.#"

K4L/?79E3H/ %$!/UYP/NOb&/%'!I/P&dQ/ ?;F86:9/#'/

O;9?/A76/A8E73?/A76/@786//NF7>HJ?7:/8B768H7/>3/cT0Q/

" " " " "NPQP " "NPQO " "NPNP"

/e82/N37F/A8E73?9Q/////// /#*!//// / /#$+/ / /)+///e82/N5;3?/A8E73?9Q//////// /#*!/ / /#$*/ / /)(///T76B>57/:7C>B76@/ / /#)(/ / /#&&/ / /##$///#9?/e>37/UYL9/ / / /#'' / /#&)/ / /')///$3:/e>37/UYL9// / /#()* / /+*& / /$+'//

P79E3H/83:/O;=397C>3H/O;B768H7/83:/5;9?/A76/A769;3/

!"#$%&'(%)*+',$%)"-,#'**'.%/,.%$'#$'.

01

021

031

041

051

061

071

081

091

0:1

1;1<12;

1<14;

1<16;

1<31;

1<51;

1<86; 6; 26

;36;

46;

56;

66;

76;

86;

96;

:6;

!"='(/>'

fTP/O;9?/U99=<AE;39/

V.()".0"6$)1-<.#$[""

•  %%5/D;6/*!<H/>3/4683/?;/0$1!(/D;6/*!<H/>3/43:;379>8/

•  U2;=?/cTb/#!!!/A76/A769;3/@786/

•  g;>3H/:;F3/2@/$!"/>3/$!#'/83:/2@/J8CD/>3/$!$!/

•  e>hC7/7B>:7357/D;6/7i75EB73799/•  e>hC7/>3D;6<8E;3/;3/5;9?/•  U9/8/A6;`@M/5;9?/F;6GAC857/A6;H68<9/N2@/$!#'I/'!"/5;B768H7/;D/?J7/#&*/<>CC>;3/7<AC;@779/>3/?J7/D;6<8C/975?;6/>3/5;=3?6>79/F>?J/H73768C>R7:/7A>:7<>59I/8B768H7/=3>?/5;9?/;D/cT0/+/A76/7<AC;@77/A76/@786Q//

X7J8B>;6/OJ83H7/d6;H68<<79/

•  e>hC7/>3D;6<8E;3/;3/5;9?//

•  O;=3?6@/67B>7F9/NcTb/#/?;/#&/A76/8:=C?/A;A=C8E;3Q//

•  O;<<=3>?@/K78C?J/[;6G769/Nj/cTb/$/A76/8:=C?/A;A=C8E;3Q//

O;<<=3>?@/a;2>C>R8E;3/